Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

DermTech, Inc. (DMTK)

6.2   0.17 (2.82%) 01-27 16:00
Open: 5.91 Pre. Close: 6.03
High: 6.27 Low: 5.8415
Volume: 760,334 Market Cap: 187(M)

Technical analysis

as of: 2023-01-27 4:43:52 PM
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 7.52     One year: 8.78
Support: Support1: 3.41    Support2: 1.54
Resistance: Resistance1: 6.44    Resistance2: 7.52
Pivot: 4.48
Moving Average: MA(5): 5.86     MA(20): 3.84
MA(100): 3.34     MA(250): 6.75
MACD: MACD(12,26): 0.9     Signal(9): 0.7
Stochastic oscillator: %K(14,3): 92.2     %D(3): 89
RSI: RSI(14): 75.9
52-week: High: 16.32  Low: 1.54
Average Vol(K): 3-Month: 831 (K)  10-Days: 1,368 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ DMTK ] has closed below upper band by 17.1%. Bollinger Bands are 203.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 6.28 - 6.31 6.31 - 6.33
Low: 5.77 - 5.81 5.81 - 5.83
Close: 6.15 - 6.2 6.2 - 6.25

Company Description

DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.

Headline News

Fri, 27 Jan 2023
DermTech Announces Inducement Grants Under NASDAQ Listing ... - Business Wire

Mon, 23 Jan 2023
DMTK stock gains on new coverage policies for melanoma test ... - Seeking Alpha

Mon, 23 Jan 2023
Will DermTech Inc (DMTK) Stay at the Top of the Healthcare Sector? - InvestorsObserver

Mon, 23 Jan 2023
2023-01-23 | NDAQ:DMTK | Press Release | DermTech Inc - Stockhouse

Wed, 18 Jan 2023
This Under-the-Radar Stock Has Tripled in 2023 -- and Could Have ... - The Motley Fool

Wed, 11 Jan 2023
DermTech Inc (DMTK) Down 1.56% in Premarket Trading - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Diagnostics & Research
Shares Out. 30 (M)
Shares Float 25 (M)
% Held by Insiders 8.1 (%)
% Held by Institutions 42.8 (%)
Shares Short 2,710 (K)
Shares Short P.Month 2,840 (K)

Stock Financials

EPS -3.16
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 5.13
Profit Margin (%) 0
Operating Margin (%) -787.3
Return on Assets (ttm) -31.2
Return on Equity (ttm) -56.3
Qtrly Rev. Growth 17.8
Gross Profit (p.s.) 0.04
Sales Per Share 0.48
EBITDA (p.s.) -3.78
Qtrly Earnings Growth 0
Operating Cash Flow -97 (M)
Levered Free Cash Flow -54 (M)

Stock Valuations

PE Ratio -1.97
PEG Ratio 0
Price to Book value 1.2
Price to Sales 12.75
Price to Cash Flow -1.94

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2019-08-29
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.